Albireo Pharma Inc (ALBO):企業の財務・戦略的SWOT分析

【英語タイトル】Albireo Pharma Inc (ALBO) - Financial and Strategic SWOT Analysis Review

GlobalDataが出版した調査資料(DATA904C13802)・商品コード:DATA904C13802
・発行会社(調査会社):GlobalData
・発行日:2019年2月
・ページ数:54
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥13,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥27,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥41,250見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Albireo Pharma Inc (ALBO) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Albireo Pharma Inc (Albireo), formerly Biodel Inc, focuses on the development and commercialization of bile acid modulators. Modulators treat orphan pediatric liver diseases and other liver and gastrointestinal (GI) disorders and diseases. The company’s lead product candidate, A4250 is a novel, minimally absorbed, orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor. The product is in a Phase III clinical trial for progressive familial intrahepatic cholestasis (PFIC), a rare, life-threatening genetic disorder affecting young children and potentially other orphan pediatric liver diseases. Albireo is located in Boston, Massachusetts, the US.

Albireo Pharma Inc Key Recent Developments

Nov 13,2018: Albireo Reports Third Quarter 2018 Financial Results
Nov 13,2018: Albireo reports third quarter 2018 financial results
Oct 17,2018: Albireo Receives FDA Fast Track Designation for A4250
Oct 17,2018: Albireo Granted Orphan Drug Designation For Lead Product Candidate A4250 for Treatment of Alagille Syndrome
Oct 15,2018: Albireo Announces Research on Cholestatic Liver Diseases to be Presented at Major North American Liver Meetings

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Albireo Pharma Inc – Key Facts
Albireo Pharma Inc – Key Employees
Albireo Pharma Inc – Key Employee Biographies
Albireo Pharma Inc – Major Products and Services
Albireo Pharma Inc – History
Albireo Pharma Inc – Company Statement
Albireo Pharma Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Albireo Pharma Inc – Business Description
Albireo Pharma Inc – Corporate Strategy
Albireo Pharma Inc – SWOT Analysis
SWOT Analysis – Overview
Albireo Pharma Inc – Strengths
Albireo Pharma Inc – Weaknesses
Albireo Pharma Inc – Opportunities
Albireo Pharma Inc – Threats
Albireo Pharma Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Albireo Pharma Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Nov 13, 2018: Albireo Reports Third Quarter 2018 Financial Results
Nov 13, 2018: Albireo reports third quarter 2018 financial results
Oct 17, 2018: Albireo Receives FDA Fast Track Designation for A4250
Oct 17, 2018: Albireo Granted Orphan Drug Designation For Lead Product Candidate A4250 for Treatment of Alagille Syndrome
Oct 10, 2018: Albireo appoints Simon Harford as chief financial officer and treasurer
Aug 07, 2018: Albireo reports second quarter 2018 financial results
Jul 25, 2018: Albireo appoints Patrick Horn as Chief Medical Officer
Jun 18, 2018: Albireo Names Jason G. Duncan As General Counsel And Secretary
Jun 08, 2018: Albireo Names Anne Klibanski and Stephanie Okey As Board Directors
May 17, 2018: Albireo Provides First Quarter 2018 Business Update
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Albireo Pharma Inc, Key Facts
Albireo Pharma Inc, Key Employees
Albireo Pharma Inc, Key Employee Biographies
Albireo Pharma Inc, Major Products and Services
Albireo Pharma Inc, History
Albireo Pharma Inc, Other Locations
Albireo Pharma Inc, Subsidiaries
Albireo Pharma Inc, Key Competitors
Albireo Pharma Inc, Ratios based on current share price
Albireo Pharma Inc, Annual Ratios
Albireo Pharma Inc, Annual Ratios (Cont...1)
Albireo Pharma Inc, Interim Ratios
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Albireo Pharma Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Albireo Pharma Inc, Performance Chart (2013 - 2017)
Albireo Pharma Inc, Ratio Charts
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

★調査レポート[Albireo Pharma Inc (ALBO):企業の財務・戦略的SWOT分析] (コード:DATA904C13802)販売に関する免責事項を必ずご確認ください。
★調査レポート[Albireo Pharma Inc (ALBO):企業の財務・戦略的SWOT分析]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆